Table 1.
Patient characteristics at baseline
| Patient characteristics | All patients (n) | Patients without hypoxic RF (n) | Patients with hypoxic RF (n) |
|---|---|---|---|
| Females | 1,693 (55) | 1,667 (55) | 26 (61) |
| Age (years) | 70 (9) | 70 (9) | 72 (8) |
| BMI (kg/m2) | |||
| <22 | 641 (21) | 635 (21) | 6 (14) |
| 22.0–29.9 | 1,753 (68) | 1,724 (58) | 29 (69) |
| ≥30 | 609 (20) | 602 (20) | 7 (17) |
| Current smoking | 938 (32) | 936 (32) | 2 (5) |
| Heart disease | 353 (12) | 343 (11) | 10 (23) |
| Sleep apnea syndrome | 57 (2) | 56 (2) | 1 (2) |
| FEV1 | 1.47 (0.60) | 1.48 (0.59) | 0.93 (0.43) |
| FEV1% pred | 53 (22) | 53 (22) | 37 (17) |
| Air flow limitation (GOLD 2017) | |||
| I | 185 (6) | 184 (6) | 1 (2) |
| II | 1,554 (51) | 1,549 (52) | 5 (12) |
| III | 1,021 (34) | 1,004 (34) | 17 (42) |
| IV | 266 (9) | 248 (8) | 18 (44) |
| Number of exacerbations in the previous year | 0.7 (1.2) | 0.7 (1.2) | 1.2 (1.6) |
| CAT score | 14 (8) | 14 (7) | 19 (8) |
| mMRC score | |||
| 0–1 | 1,160 (49) | 1,158 (50) | 2 (5) |
| 2 | 535 (23) | 528 (23) | 7 (19) |
| 3 | 354 (15) | 344 (15) | 10 (27) |
| 4 | 317 (13) | 299 (13) | 18 (49) |
| Symptoms/exacerbations (GOLD 2017) | |||
| A | 491 (29) | 489 (29) | 2 (8) |
| B | 877 (52) | 862 (52) | 15 (58) |
| C | 43 (3) | 42 (3) | 1 (4) |
| D | 279 (17) | 271 (16) | 8 (31) |
| Treatment | |||
| LAMA monotherapy | 426 (14) | 426 (14) | 0 (0) |
| LABA monotherapy | 62 (2) | 62 (2) | 0 (0) |
| LAMA and LABA | 134 (4) | 132 (4) | 2 (5) |
| LABA and ICS | 325 (11) | 320 (11) | 5 (12) |
| LAMA, LABA, and ICS | 1,133 (37) | 1,101 (37) | 32 (74) |
Note: Data are presented as frequency (column percentages) or mean (standard deviation).
Abbreviations: BMI, body mass index; CAT, COPD assessment test; FEV1, forced expiratory volume in 1 second; FEV1% pred, FEV1% of predicted value; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting beta-2 agonists; LAMA, long-acting muscarinic antagonists; mMRC, modified Medical Research Council; RF, respiratory failure.